PT-112’s mechanism of action inhibits ribosomal biogenesis, promoting immunogenic cancer cell death through cancer cell organelle stresses Data presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting NEW YORK, Nov. 4, 2023 /PRNewswire/ — Promontory Therapeutics Inc., a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.